The kinetics of circulating Candida mannan and anti-mannan antibodies were studied in consecutive plasma samples, obtained upon hospital admission, of 21 patients with microbiologically proven invasive candidiasis and 30 control patients who underwent myelo-ablative chemotherapy. The detection of Candida anti-mannan antibodies preceded the diagnosis of invasive candidiasis in infected patients, and the antibodies were detected significantly more often in patients who had experienced multiple episodes of neutropenia than in the control group (OR 8.9, 95% CI 5.6-14.3; p <0.05). Mannan was predominantly detected in patients who developed invasive candidiasis during their first episode of neutropenia (OR 3.7, 95% CI 1.4-9.7; p <0.05). This observation suggests that patients with multiple episodes of neutropenia have been previously exposed to Candida and that the presence of anti-mannan antibodies in these patients might be associated with an increased risk of developing clinically manifest invasive candidiasis.
Introduction
Invasive Candida infections continue to be associated with significant morbidity and mortality [1] , despite the availability of new potent antifungal agents such as the echinocandins [2, 3] . One of the factors that has emerged as pivotal in improving the outcome of patients with invasive candidiasis is the timing of initiation of antifungal therapy [4, 5] ; these studies have shown that any delay reduces the chance of survival. However, this window of opportunity is lost when treatment is initiated on the basis of positive blood cultures, due to the relatively long time to detection for Candida species when using commercial blood culture systems [6] . Biological markers are increasingly used for the early diagnosis of opportunistic fungal infections in immunocompromised patients, and these primarily involve systems that detect circulating fungal antigens [7] . The sensitivity and specificity of these systems vary, ranging from 0% to 100% and from 88% to 100%, respectively, due to differences in methodology and different patient groups [8] [9] [10] [11] [12] [13] [14] . Although the systems available for diagnosing invasive Candida infection combine mannan and anti-mannan antibody detection, the role of antibody detection is limited, especially in neutropenic patients. It is generally accepted that in this patient population, antibodies are not an early marker of invasive fungal infection and, at best, are present after the infection and following immune recovery [15] .
The kinetics of Candida-specific mannan antigen and antimannan antibodies were studied in patients with haematological malignancy and invasive Candida infection, using a commercially available system (Platelia Candida Ag and Platelia Candida Ab/Ac/Ak; BioRad, Marnes-La-Coquette, France) in order to establish whether such systems could identify patients who require early and reliable antifungal therapy.
Subjects, Materials and Methods

Study design
The microbiological records of patients admitted to a tertiary-care hospital for intensive cytotoxic chemotherapy for a malignancy or to undergo allogenic haematopoietic stem cell transplantation between January 1999 and December 2005, and who had microbiologically proven invasive candidiasis, were reviewed. Invasive candidiasis was defined according to at least one positive culture from blood or normally sterile tissue samples. A second selection criterion was the availability of one or more stored serum or plasma samples within a 4-week period preceding the microbiological diagnosis. The duration of neutropenia, defined as a neutrophil count of <0.5 · 10 9 /L, was recorded for every patient. The mean number of days of neutropenia for a single course of chemotherapy was 8 days (standard deviation ±6 days). Therefore, 15 days was chosen as a cut-off to categorize patients for further analysis as those with <15 days and those with >15 days of neutropenia prior to microbiological confirmation of Candida infection, which corresponds to a single course or multiple courses of chemotherapy, respectively. Background reactivity of the enzyme immunoassays (EIAs) was studied in a matched control group of patients admitted to the same ward within the same study period as the patients with invasive candidiasis, but without documented invasive Candida infection. Besides microbiological data, the underlying disease, cytotoxic and antimicrobial treatment regimens were recorded for all patients. Experimentation guidelines for humans from the Radboud University Nijmegen Medical Centre were followed in the conduct of this research.
Sampling and microbiology
All admitted patients were intensively monitored, and this included the twice-weekly sample collection for blood cultures from each lumen of the four-lumen central venous catheter during episodes of neutropenia. Twice weekly, samples from mouthwashes and faeces were obtained and cultured for the presence of Gram-negative rods and Candida spp. Oral fluconazole at a dose of 200 mg/day was pre-emptively given to patients colonized with Candida albicans. Colonization was defined according to two subsequent positive cultures from mouthwashes and/or faeces without clinical signs of infection. When a patient developed fever, additional blood samples were drawn from the central venous catheter and by venipuncture. Febrile patients were empirically treated with ceftazidime. Patients with invasive yeast infection were treated with fluconazole at a dose of 400 mg/day. Serum or plasma was systemically collected twice weekly during the neutropenic episodes of hospitalized patients and was stored until use at )80°C. Blood cultures were incubated for 5 days in an automated blood culture system (Bactec; Becton Dickinson, Breda, The Netherlands). All Candida isolates were identified to the species level using their ability to produce a germ-tube when incubated with fetal bovine serum and by biochemical identification for germtube-negative yeasts (Auxacolor II; Biorad Laboratories).
Laboratory studies
All available serum or plasma samples were analysed for the presence of Candida-specific mannan and anti-mannan antibodies. For the detection of mannan, the Platelia Candida Ag assay (BioRad) was used, and for anti-mannan antibody detection, the Platelia Candida Ab/Ac/Ak assay (BioRad) was used. Microtitre plates of the BioRad mannan and antibody assays are coated with monoclonal anti-mannan antibody, EBCA-1, and C. albicans cell wall mannan, respectively. All assays were performed according to the manufacturer's instructions. For the BioRad mannan EIA, a result lower than 0.25 lg/L was considered to be negative, and for the BioRad anti-mannan antibody EIA, results lower than 5 AU/mL were considered to be negative.
Analysis
The Mann-Whitney U-test was applied to compare means. For comparing proportions, a per-sample analysis and a perpatient analysis were performed. A positive patient was defined as one having at least two antigen-positive or antimannan antibody-positive samples. Fisher exact tests were used to evaluate differences in proportions, and the ORs were calculated.
Results
The patient group with a microbiologically proven invasive Candida infection included 21 patients (13 male, eight female) with a mean age of 40 years (range 3-65 years). Nineteen (90.5%) patients were treated for a haematological malignancy, and two patients were treated for a non-haematological malignancy (Table 1) . Twelve of 21 patients were infected with C. albicans. The remaining nine patients were infected with other Candida species: Candida glabrata (three), Candida tropicalis (two), Candida krusei (one), Candida dubliniensis (one), Candida parapsilosis (one), and Candida lusitaniae (one). Ten and 11 patients were neutropenic for <15 days and >15 days, respectively. Nineteen of 21 patients were colonized with the same species before their infection was microbiologically documented; in one patient, the presence of yeast colonization was unknown, and one was not previously colonized. In total, 242 serum samples were available for testing, being collected from each patient from the first day of admission until final discharge, which ranged from 339 days before to 253 days after invasive candidiasis was microbiologically proven (Table 1) . Mannan and anti-mannan antibodies were detected in plasma samples of 15 patients before the infection was microbiologically proven. The mean proportion of antigen-positive or antibody-positive plasma samples per patient was 60% (range 0-100%).
The control group included 30 patients (19 male, 11 female) with a mean age of 49 years (range 26-64 years). Underlying diseases are shown in Table 1 . Five patients were neutropenic during their hospital stay for <15 days, and the remaining 25 patients were neutropenic for >15 days. Twenty control patients (67%) were colonized with yeasts, 12 with C. albicans, seven with C. albicans together with other Candida spp., and one with only non-albicans Candida spp.
Four control patients had clinical signs, and there was microbiological evidence of a superficial Candida infection.
Severe mucosal barrier injury was present in 24 patients. In total, 390 serum samples were available for testing. The mean number of available samples per patient was comparable to the mean number of collected samples in the group of patients with invasive candidiasis (p >0.05; Mann-Whitney U-test). The number of antigen-positive or antibody-positive plasma samples ranged from zero to three, except for two patients, where nine of 11 (82%) and 20 of 34 (59%) samples were positive for anti-mannan antibody. These consecutive samples were collected in periods of 35 and 207 days, respectively. Except for these two patients, no distinct pattern was observed in the remaining patients of this group. The mean proportion of positive samples was 20% (range 0-100%), which differed significantly from the mean proportion of positive samples in the infected group (p <0.05, Mann-Whitney U-test). Mucosal barrier injury, prior colonization, superficial Candida infections and fluconazole usage were not associated with the detection of mannan antigen or anti-mannan antibody, according to logistic regression analysis using the 'Enter' method (p >0.05).
Anti-mannan antibodies were generally detected earlier than mannan in samples of infected patients, with median numbers of 23 days for the anti-mannan antibodies and 1 day for mannan, before the infection was microbiologically proven (Table 2 ). This pattern remained when the patients were subdivided into those who were infected with C. albicans and those who were infected with non-albicans Candida species (data not shown). Mannan was detected significantly more often in samples from infected patients with <15 days of neutropenia prior to the diagnosis of invasive candidiasis than in those with >15 days of neutropenia ( Fig. 1 ; Fisher exact test, p <0.05). However, anti-mannan antibodies were detected significantly more often in samples collected from infected patients with >15 days of neutropenia prior to with <15 days and >15 days of neutropenia were 3.7 (95% CI 1.4-9.7) and 1.3 (95% CI 0.6-3.3), respectively. Mean mannan levels in samples from patients with invasive candidiasis and <15 days of neutropenia were significantly higher than those in the control group. For patients with >15 days of neutropenia, no significant differences in antigen levels in the collected samples were observed ( Table 3) . The proportions of anti-mannan antibody-positive samples from infected and non-infected patients with <15 days of neutropenia were 18% and 0%, respectively, and 52% and 11%, respectively, in samples from infected and control patients with >15 days of neutropenia. These differences were significant (p <0.05, Fisher exact test; Table 2 ). The corresponding OR for anti-mannan antibody-positive samples of infected patients with <15 days of neutropenia could not be calculated; for infected patients with >15 days of neutropenia, the OR was 8.9 (95% CI 5.6-14.3). In the per-patient analysis, the proportion of antibody-positive patients with >15 days of neutropenia was significantly higher in the infected group than in the control group (p <0.05, Fisher exact test). The corresponding OR for a positive sample was 12.8 (95% CI 2.3-71.8). Comparisons between infected patients and those of the control group with <15 days of neutropenia who were antigen-positive or antibody-positive revealed no significant differences.
Discussion
The present study investigated the kinetics of circulating Candida-specific mannan and anti-mannan antibodies in patients undergoing myelo-ablative therapy with microbiologically proven invasive candidiasis. Anti-mannan antibodies were predominantly found in patients with >15 days of neutropenia prior to microbiological documentation of invasive candidiasis. Differences, both in the per-sample and in the per-patient analysis, were statistically significant when compared with the control group, which included patients who were colonized or had superficial infections with Candida. In this study, these factors did not contribute to plasma reactivity. Mannan was predominantly detected in patients who developed invasive candidiasis during their first course of chemotherapy, as reflected by the significant differences between samples from infected and non-infected patients with <15 days of neutropenia. The predominance of antimannan antibodies in patients who were neutropenic for >15 days indicates that, during previous episodes of neutropenia, a clinically undetected Candida infection occurred, thereby exposing the host to Candida cells or antigen. With recovery of the neutrophils, an antibody response can be detected. The kinetics as observed in individual patients are consistent with this explanation (Fig. 3) . In patients who developed invasive candidiasis during their first course of chemotherapy, circulating mannan was the first indicator of infection, suggesting different kinetics of these biological markers. In these patients, the immune system has not been exposed to Candida or its antigens before, and consequently circulating antibodies are not present. No distinguishable pattern in the kinetics of antigen levels as shown in Fig. 1 was observed in the control group, as illustrated in an individual patient in Fig. 4 . This was also true for control patients who were categorized as positive in the per-patient analysis, with the exception of the two individuals described earlier.
It could be that these two patients had suffered from a clinically undetected Candida infection. Thus, the mere presence of antigen or antibody in one or two samples does not necessarily mean that the patient is, or has been, infected.
Although others have investigated the kinetics of Candida antigen and antibodies in neutropenic patients [10, 16, 17] , the window of sampling in these studies was restricted to the period shortly before and/or after the microbiological diagnosis was made. The present study, which investigated all samples collected during consecutive treatment cycles, suggests that circulating antibodies constitute a very early indicator of invasive candidiasis in patients with multiple episodes of neutropenia, an observation that is similar to that recently reported for invasive aspergillosis. Antibodies directed against recombinant Aspergillus cell wall antigens were found in serum samples, obtained at admission, of c. 50% of the patients who eventually developed invasive aspergillosis [18] . In both invasive aspergillosis and invasive candidiasis, the pathogenesis of the infection is largely unknown; the present observation and that of Sarfati et al. [18] indicate that subclinical infections are likely to occur before clinically manifest disease develops and microbiological confirmation by culture is achieved. Therefore, antibody detection might be a very valuable biological marker that will help to identify those patients who are at increased risk of developing these invasive fungal diseases, and also to target intervention strategies. However, the present study was limited by the relatively small sample size, especially in the group with <15 days of neutropenia, and therefore provides only a 'proof of concept'. Prospective studies are required to confirm this observation before the benefit of such strategies can be evaluated.
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